1. Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court’s Recent Rulings do not Solve Fundamental Barriers to Competition

   • Brian K. Chen
   • Y. Tony Yang
   • Charles L. Bennett

   Current Opinion 16 November 2018 Pages: 1777 - 1781

2. A Critical Review of Nebivolol and its Fixed-Dose Combinations in the Treatment of Hypertension

   • Arrigo F. G. Cicero
   • Masanari Kuwabara
   • Claudio Borghi

   Review Article 13 November 2018 Pages: 1783 - 1790

   

3. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis

   • Simona Lattanzi
   • Francesco Brigo
   • Mauro Silvestrini

   Systematic Review 03 November 2018 Pages: 1791 - 1804

   

4. Tapentadol Prolonged Release: A Review in Pain Management

   • Emma D. Deeks

   Adis Drug Evaluation Open access 23 November 2018 Pages: 1805 - 1816

   

5. Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection

   • Emma D. Deeks

   Adis Drug Evaluation Open access 20 November 2018 Pages: 1817 - 1828

6. Fremanezumab: First Global Approval

   • Sheridan M. Hoy

   AdisInsight Report Open access 08 November 2018 Pages: 1829 - 1834

   

7. Vibegron: First Global Approval

   • Susan J. Keam

   AdisInsight Report 08 November 2018 Pages: 1835 - 1839

   

8. Cemiplimab: First Global Approval

   • Anthony Markham
   • Sean Duggan

   AdisInsight Report 19 November 2018 Pages: 1841 - 1846

   

9. Duvelisib: First Global Approval

   • Hannah A. Blair

   AdisInsight Report 14 November 2018 Pages: 1847 - 1853

   

10. Correction to: Elagolix: First Global Approval

    • Yvette N. Lamb

    Correction Open access 15 November 2018 Pages: 1855 - 1855